MedWatch

Leo Pharma: Approval opens up a huge market

US approval of a new indication for a gel product opens up an extremely interesting market for the Danish company Leo Pharma.

“With this product and our solar keratosis product Picato, which we launched on the US market earlier this year, we find ourselves in a situation where a new market has opened up, which is actually bigger than our total market so far,” says Jacob Anker Rasmussen, VP of Global Sales and Marketing in Leo Pharma.

His words stress the importance of FDA’s recent approval of Leo Pharma’s gel product, Taclonex, for a new indication within psoriasis.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier